Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Adenylosuccinate lyase deficiency (ADSL deficiency) is a disorder of purine metabolism characterized by intellectual disability, psychomotor delay and/or regression, seizures, and autistic features.
Features include always present findings: Global developmental delay; and very common findings: Long philtrum, Anteverted nares, Seizure, and Short nose and others. 44 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 15 | Hemiplegia, Inability to walk, Seizure |
Muscles | 5 | Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Generalized hypotonia |
Head and neck | 3 | Thin upper lip vermilion, Microcephaly, Abnormal facial shape |
Eyes | 2 | Strabismus, Nystagmus |
Bones and joints | 2 | Severe backward arching of the body (opisthotonus), Skeletal muscle atrophy |
Growth and development | 1 | Growth delay |
Kidneys and urinary system | 1 | Elevated urinary succinylaminoimidazole carboxamide riboside level |
ADSL encodes adenylosuccinate lyase (484 aa). Catalyzes two non-sequential steps in de novo AMP synthesis: converts (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate (SAICAR) to fumarate plus 5-amino-1-(5-phospho-D-ribosyl)i... Highest expression in Muscle Skeletal (55.2 TPM) and Cells EBV-transformed lymphocytes (41.8 TPM).
Adenylosuccinate lyase deficiency is caused by mutations in the ADSL gene on chromosome 22.
ADSL is classified as a druggable target (Enzyme category) with score 0.0.
77 pathogenic variants reported in ADSL in ClinVar, including hotspot variants 529212 and 451308.
Variant | Significance | Review Stars | Hotspot |
|---|---|---|---|
529212 | Conflicting classifications of pathogenicity | — | Yes |
451308 | Conflicting classifications of pathogenicity | — | Yes |
450065 | Conflicting classifications of pathogenicity | — | Yes |
235410 | Conflicting classifications of pathogenicity | — | Yes |
Genetic testing for ADSL is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 18 very common features, 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
6 publications have been identified in PubMed for adenylosuccinate lyase deficiency. Research spans Case Report / Case Series (33%), Basic Science / Preclinical (33%), and Review / Meta-Analysis (17%).
Klapperich A (2026). [PMID: 41617613](https://pubmed.ncbi.nlm.nih.gov/41617613/). *Prenat Diagn*. [Case Report / Case Series]
Borovikov A (2025). [PMID: 41211455](https://pubmed.ncbi.nlm.nih.gov/41211455/). *Front Genet*. [Case Report / Case Series]
Rousselot-Pailley B (2025). [PMID: 41053929](https://pubmed.ncbi.nlm.nih.gov/41053929/). *J Inherit Metab Dis*. [Clinical Trial Publication]
Bordi M (2025). [PMID: 40914938](https://pubmed.ncbi.nlm.nih.gov/40914938/). *Cell Rep*. [Basic Science / Preclinical]
Magnusen AF (2025). [PMID: 40896413](https://pubmed.ncbi.nlm.nih.gov/40896413/). *Brain Behav Immun Health*. [Review / Meta-Analysis]
Patil RR (2025). [PMID: 41101294](https://pubmed.ncbi.nlm.nih.gov/41101294/). *Mol Genet Metab*. [Basic Science / Preclinical]
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 3:02 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adenylosuccinate lyase deficiency